This Program Project application represents a comprehensive collaborative effort by six senior investigators in two Departments of the University of Arizona to carry out a systematic investigation for the development of highly opioid receptor selective and efficacious peptide ligands that will provide nonaddictive opioid analgesics, and new modalities for the treatment of pain, drug dependence and opioid withdrawal. We emphasize studies that will provide new insights for the design of peptide, and peptide conjugate structures that will lead to new modalities for treatment of pain and drug abuse. Consortium and local arrangements have been made that will provide the preclinical data that for the first time will lead to human clinical trials for delta agonists. A highly cooperative multi-disciplinary approach involving computer aided drug design, biophysics, asymmetric synthesis, macrocyclic synthesis, binding studies, in vitro and in vivo assays, and examination of second messenger andother aspects of signal transduction has been established. Strong collaborative interactions will be emphasized with the following major specific aims: 1) to further develop a systematic approach to computer aided design of delta opioid receptor potent and selective peptide ligands that have unique profiles of biological activity, are biostable, can penetrate through the blood-brain barrier (BBB), and are highly efficacious agonists with analgesic activity; 2) prodrug approaches, and carrier mediated mechanisms, which favor passage of peptides and peptide conjugates through the BBB will be examined; 3) to utilize site specific mutagenesis, chimeric structures, second messenger studies, etc. in conjunction with modeling of the human clone delta and other opioid receptors to provide new understanding of the structural basis for agonist and antigonist activity of opioid ligands and the mechanisms of action of opioids; 4) to utilize state of the art pharmacological studies including, antisense deoxyribonucleotides, models of nonciception, and physical dependence including self-administration to obtain new insights into the mechanisms of action of biphalin, [Phe6]DPDPE and other ligands that have unique biological activity profiles including unprecedented efficacy enhancement and minimal side effects; 5) to perform the necessary preclinical toxicity studies needed to eventually file an investigator sponsored investigational New Drug Application (INDA) for human trials for DPDPE and biphalin; 6) to comprehensively examine peptide analogues stability, chemical-physical properties, distribution, bioconversion, and pharmacokinetics in relation to their ability to cross the BBB; 7) to utilize core facilities to prepare quantities of compounds needed for in vitro and in vivo bioassays to obtain more potent, efficacious peptides that can cross the BBB; 8) to develop an understanding of the molecular, dynamic and conformational properties of peptides, and peptide conjugate ligands thatmaximize penetration of the BBB.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
2P01DA006284-08A1
Application #
2013021
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Rapaka, Rao
Project Start
1989-09-30
Project End
2002-03-31
Budget Start
1997-05-15
Budget End
1998-03-31
Support Year
8
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Arizona
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Remesic, Michael; Macedonio, Giorgia; Mollica, Adriano et al. (2018) Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors. Bioorg Med Chem 26:3664-3667
Mowlazadeh Haghighi, Saghar; Zhou, Yang; Dai, Jixun et al. (2018) Replacement of Arg with Nle and modified D-Phe in the core sequence of MSHs, Ac-His-D-Phe-Arg-Trp-NH2, leads to hMC1R selectivity and pigmentation. Eur J Med Chem 151:815-823
Sandweiss, A J; McIntosh, M I; Moutal, A et al. (2018) Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential. Mol Psychiatry 23:1745-1755
Bannister, Kirsty; Qu, Chaoling; Navratilova, Edita et al. (2017) Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain 158:2386-2395
Vardanyan, Ruben S; Cain, James P; Haghighi, Saghar Mowlazadeh et al. (2017) Synthesis and Investigation of Mixed ?-Opioid and ?-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain. J Heterocycl Chem 54:1228-1235
Cai, Minying; Marelli, Udaya Kiran; Mertz, Blake et al. (2017) Structural Insights into Selective Ligand-Receptor Interactions Leading to Receptor Inactivation Utilizing Selective Melanocortin 3 Receptor Antagonists. Biochemistry 56:4201-4209
Deekonda, Srinivas; Rankin, David; Davis, Peg et al. (2016) Design synthesis and structure-activity relationship of 5-substituted (tetrahydronaphthalen-2yl)methyl with N-phenyl-N-(piperidin-2-yl)propionamide derivatives as opioid ligands. Bioorg Med Chem 24:85-91
Lee, Yeon Sun; Remesic, Michael; Ramos-Colon, Cyf et al. (2016) Cyclic non-opioid dynorphin A analogues for the bradykinin receptors. Bioorg Med Chem Lett 26:5513-5516
Remesic, Michael; Lee, Yeon Sun; Hruby, Victor J (2016) Cyclic Opioid Peptides. Curr Med Chem 23:1288-303
Ramos-Colon, Cyf N; Lee, Yeon Sun; Remesic, Michael et al. (2016) Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the ? Opioid Receptor. J Med Chem 59:10291-10298

Showing the most recent 10 out of 268 publications